Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy
A dual‐domain framework is proposed in which tau‐targeted therapies are evaluated using complementary measures of aggregated tau burden and biologically defined soluble tau states, and treatment‐induced increases should be considered favorable only when they accompany aggregate reduction and evidence of a less pathogen...